Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Patient Activation Clear all
Completed Phase 3 Interventional Results available

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

NCT00949650
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions
Pemetrexed, BIBW 2992, Cisplatin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Fayetteville, Arkansas • Montebello, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Not applicable Interventional

Safety and Performance of Muscle Activation for Critical Care Patients

NCT01552616
View directory record Official record
Conditions
Critically-ill
Interventions
Thermal-aided muscle activation
Procedure
Lead sponsor
Niveus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Baltimore, Maryland • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

Caring Others Increasing EngageMent in PACT

NCT02328326
View directory record Official record
Conditions
Diabetes
Interventions
CO-IMPACT, PACT
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 70 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Results available

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

NCT03007719
View directory record Official record
Conditions
Bladder Cancer
Interventions
Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Everolimus for Cancer With TSC1 or TSC2 Mutation

NCT02201212
View directory record Official record
Conditions
TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
Interventions
Everolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

Vitamin D in HIV-Infected Patients on HAART

NCT01250899
View directory record Official record
Conditions
Vitamin D Deficiency, HIV
Interventions
Vitamin D
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia

NCT00793520
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

NCT02023905
View directory record Official record
Conditions
Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas, Oligodendrogliomas, Mixed Oligoastrocytomas
Interventions
Everolimus, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

Diabetes Outcomes and Unmet Resources

NCT03950973
View directory record Official record
Conditions
Diabetes
Interventions
CareAvenue, Guest Assistance Program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Phase 1 Interventional

Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant

NCT00674427
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions
CD3/CD28 Activated T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia

NCT00020670
View directory record Official record
Conditions
Leukemia
Interventions
CD 40
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 22, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

NCT04233073
View directory record Official record
Conditions
Surgery
Interventions
andexanet alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Patient Activation in High-Risk Patients With Heart Failure

NCT00260650
View directory record Official record
Conditions
Heart Failure
Interventions
Heart PACT Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 22, 2026, 2:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291
View directory record Official record
Conditions
Melanoma
Interventions
Fianlimab, Cemiplimab, Pembrolizumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 2:13 PM EDT
Recruiting No phase listed Observational

Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

NCT07125079
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

NCT01173055
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

NCT00525148
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Jul 22, 2026, 2:13 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

NCT00022230
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, sargramostim, therapeutic autologous lymphocytes, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 22, 2026, 2:13 PM EDT
Completed No phase listed Observational

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

NCT00996047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
3,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2012
U.S. locations
280
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:

NCT04488497
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Diseases, Hyperlipidemias
Interventions
Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis, Standard of care
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 22, 2026, 2:13 PM EDT
Recruiting No phase listed Observational

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

NCT07143669
View directory record Official record
Conditions
Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Interventions
Screening
Other
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 2:13 PM EDT
Completed No phase listed Observational

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

NCT00898079
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
2,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
175
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 1 Interventional

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

NCT00868595
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer (CRPC)
Interventions
BPX-101, AP1903
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 22, 2026, 2:13 PM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 22, 2026, 2:13 PM EDT